Exelixis, Inc.
EXEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000939767
In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.
Superinvestors holding EXEL, Q2 2026
No superinvestor reported holding EXEL in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of EXEL each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2021
0 superinvestors holding at quarter end
- Sold out
- Maverick Capital
Q3 2021
1 superinvestor holding at quarter end
- Reduced
- Maverick Capital (−25.2%)
Q2 2021
1 superinvestor holding at quarter end
- Added
- Maverick Capital (+209.4%)